[3]
(a)Pomerantz, R.J.; Horn, D.L. Twenty years of therapy for HIV-1 infection. Nat. Med., 2003, 9, 867-873.
(b)Lu, D.Y.; Wu, H.Y.; Yarla, N.S.; Xu, B.; Ding, J.; Lu, T.R. HAART in HIV/AIDS Treatments: Future trends. Infect. Disord. Drug Targets, 2018, 18(1), 15-22.
(b)Lu, D.Y.; Wu, H.Y.; Yarla, N.S.; Xu, B.; Ding, J.; Lu, T.R. HAART in HIV/AIDS Treatments: Future trends. Infect. Disord. Drug Targets, 2018, 18(1), 15-22.
[4]
FDA-approved HIV medicines.; (Available at: https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/58/fda-approved-HIV-medicines
[5]
Zhan, P.; Pannecouque, C.; De-Clercq, E.; Liu, X. Anti-HIV drug discovery and development: Current innovations and future trends. J. Med. Chem., 2016, 59, 2849-2878.
[6]
Voshavar, C. Protease inhibitors for the treatment of HIV/AIDS: Recent advances and future challenges. Curr. Top. Med. Chem., 2019, 19(18), 1571-1598.
[7]
Suttisintong, K.; Kaewchangwat, N.; Thanayupong, E.; Nerungsi, C.; Srikun, O.; Pungpo, P. Recent progress in the development of HIV-1 entry inhibitors: From small molecules to potent anti-HIV agents. Curr. Top. Med. Chem., 2019, 19(18), 1599-1620.